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Abstract
The selection and soaring spread of Mycobacterium tuberculosis multidrug-resistant (MDR-TB) and extensively drug-resistant
strains (XDR-TB) is a severe public health problem. Currently, there is an urgent need for new drugs for tuberculosis
treatment, with novel mechanisms of action and, moreover, the necessity to identify new drug targets. Mycobacterial
phosphoribosylpyrophosphate synthetase (MtbPRPPase) is a crucial enzyme involved in the biosynthesis of decaprenylpho-
sphoryl-arabinose, an essential precursor for the mycobacterial cell wall biosynthesis. Moreover, phosphoribosylpyrophos-
phate, which is the product of the PRPPase catalyzed reaction, is the precursor for the biosynthesis of nucleotides and of
some amino acids such as histidine and tryptophan. In this context, the elucidation of the molecular and functional features
of MtbPRPPase is mandatory. MtbPRPPase was obtained as a recombinant form, purified to homogeneity and characterized.
According to its hexameric form, substrate specificity and requirement of phosphate for activity, the enzyme proved to
belong to the class I of PRPPases. Although the sulfate mimicked the phosphate, it was less effective and required higher
concentrations for the enzyme activation. MtbPRPPase showed hyperbolic response to ribose 5-phosphate, but sigmoidal
behaviour towards Mg-ATP. The enzyme resulted to be allosterically activated by Mg
2+ or Mn
2+ and inhibited by Ca
2+ and
Cu
2+ but, differently from other characterized PRPPases, it showed a better affinity for the Mn
2+ and Cu
2+ ions, indicating a
different cation binding site geometry. Moreover, the enzyme from M. tuberculosis was allosterically inhibited by ADP, but
less sensitive to inhibition by GDP. The characterization of M. tuberculosis PRPPase provides the starting point for the
development of inhibitors for antitubercular drug design.
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Introduction
Mycobacterium tuberculosis, which is the etiologic agent of
tuberculosis (TB), was discovered in 1882 by the German
physician Robert Koch. TB was already then considered one of
the most dangerous infectious diseases but, continues to still be,
unfortunately, a major cause of death in underdeveloped nations,
and a re-emerging disease in developed countries. Moreover, TB is
currently endemic in the regions of sub-Saharan Africa, where
susceptibility of HIV-infected people in developing the disease
continuously increases [1].
According to the World Health Organization (WHO), in 2006
there were 9.2 million new cases of TB, and 1.7 million deaths from
the disease, of which 95% occurred in low-income countries [2]. TB
treatment is made more difficult by the emergence of multidrug
resistantstrains(MDR-TB),i.e.strainsresistanttotwoofthefirst-line
drugs, either isoniazid or rifampicin. MDR-TB demands treatment
with second-line drugs [3–4]. Lately, a still more dangerous form of
tuberculosis, i.e. extensively drug-resistant tuberculosis (XDR-TB),
has been identified in all regions of the world and is becoming an
alarming growing global health problem [5].
For these reasons, an emergence of a global plan to stop TB is
necessary and needs the designing of new drugs and the
identification of new molecular targets [6–7].
Recent studies have shown that, because of the mycobacterial cell
wall’s importance as a virulence factor in pathogenicity, it is thus
rich in promising drug targets [8]. The mycobacterial cell wall
structure is very complex and highly hydrophobic. It is character-
ized on the outer side by a mycolic acid layer and on the inner side
by a peptidoglycan layer. These two layers are linked together by an
arabinogalactan complex. It has been demonstrated that enzymes
involved in arabinogalactan biosynthesis are essential for the
livelihood of M. tuberculosis [9]. This makes these enzymes ideal
targets for designing new antitubercular drugs.
Recently, Makarov et al. [10] demonstrated that benzothiazi-
nones, which are a new generation class of antitubercular drugs,
act inhibiting M. tuberculosis DprE1 activity, an essential membrane
associated enzyme [11–12] that works in concert with the DprE2
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ribose (DPR) to decaprenylphosphoryl-arabinose (DPA), which is a
precursor for arabinan synthesis [12]. It is noteworthy that without
DPA, a complete mycobacterial cell wall cannot be produced [12].
Within the DPA biosynthesis pathway, other enzymes could be
considered potential antitubercular targets such as the phospho-
ribosylpyrophosphate synthetase (PRPPase).
PRPPase (EC 2.7.6.1) catalyzes the transfer of the b,c-
pyrophosphoryl group from the Mg
2+ ATP complex (Mg-ATP)
to ribose 5-phosphate (R5P) in order to form 5-phosphoribosyl-1-
pyrophosphate (PRPP) [13], which is the precursor for the
biosynthesis of purine and pyrimidine nucleotides, as well as of
pyridine nucleotides coenzymes and of the amino acids histidine
and tryptophan [14]. M. tuberculosis PRPPase (MtbPRPPase), which
is encoded by the rv1017c (prsA) gene, is also involved in the
biosynthesis of DPA [12] (Fig. 1).
Three different classes of PRPPase have been described so far
with distinctive enzymatic properties, such as the requirement of
phosphate ions for activity and allosteric regulation and specificity
for the diphosphoryl donor. Most PRPPases belong to class I, and
are also named ‘‘classical’’ PRPPases. These enzymes, which
require phosphate and Mg
2+ ions, are allosterically inhibited by
ADP and, possibly, by other nucleotides, and exclusively use ATP
or, in some instances, also dATP as diphosphoryl donors [15–17].
Class II PRPPases are specific for plants and are characterized by
the independence of phosphate ions and the lack of allosteric
inhibition by purine ribonucleoside diphosphates. Moreover, class
II PRPPases have a broad specificity for diphosphoryl donors
using GTP, CTP or UTP in addition to ATP and dATP [18–20].
Finally, a new class III PRPPase has been recently described, from
the archaeon Methanocaldococcus jannaschii. This enzyme is activated
by phosphate and uses ATP as a diphosphoryl donor. Conversely,
it is devoid of the allosteric site for ADP [21].
The crystal structures of Bacillus subtilis and human isoform 1
(class I) [22–23], as well as M. jannaschii (class III) PRPPase have
been solved [21]. Class I enzymes are hexamers of identical
subunits, which consist of two domains that are organized as a
propeller with the N-terminal domains at the centre and the C-
Figure 1. The biosynthesis pathway of decaprenylphosphoryl arabinose in mycobacteria. The figure was adapted from Wolucka BA
(2008) Biosynthesis of D-arabinose in mycobacteria – a novel bacterial pathway with implications for antimycobacterial therapy. FEBS Journal 275:
2691–2711. Reproduced with permission.
doi:10.1371/journal.pone.0015494.g001
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located at the interface between the domains of each subunit,
whereas the allosteric sites are at the interface between the three
subunits of the hexamer. On the contrary, the class III PRPPase is
tetrameric. The active sites are at the interface between the
domains of the subunits, although no allosteric sites have been
found [21].
Our laboratory is aimed at producing enzymes involved in the
DPA synthesis, such as DprE1 [10], for structural studies and drug
design, as we believe that the enzymes belonging to this pathway
could represent a ‘‘weak ring of the chain’’ [24].
In this context, the PRPPase enzyme seems very promising
being essential as shown by Himar1-based transposon mutagenesis
in the M. tuberculosis H37Rv strain [25] and is furthermore
involved in two important pathways: the DPA, and purine/
pyrimidine nucleotides biosyntheses.
In this work, the biochemical characterization of the M.
tuberculosis PRPPase obtained in recombinant form is reported, as
a basis for the identification of a potential antitubercular drug
target.
Materials and Methods
Strains and Growth Conditions
All cloning steps were performed in Escherichia coli DH5a grown
in Luria-Bertani (LB) broth or on LB agar. The expression strain
was E. coli BL21(DE3)pLysS. When necessary, antibiotics (Sigma)
were added at the following concentrations: ampicillin, 100 mg/
ml; chloramphenicol, 34 mg/ml; kanamycin, 50 mg/ml. All strains
were grown aerobically at 37uC with shaking at 200 rpm.
Cloning of rv1017c Gene in pET28-a Expression Vector
The rv1017c gene (prsA) encoding MtbPRPPase, was amplified
by PCR from the genomic DNA of M. tuberculosis H37Rv using
Taq DNA Polymerase (Qiagen) with primers Rv101728aF (59-
TTGGATCCTTGAGCCACGACTGG-39; BamHI restriction
site is underlined) and Rv1017R (59-TTAAGCTTCTATGCG-
TCCCCGTCG-39; HindIII restriction site is underlined). The
PCR reaction was performed by using the MJ Mini Personal
Thermal Cycler (BioRad). The resulting amplified fragment
(981 bp) was purified with a Wizard PCR Prep mini-column
(Promega), digested with BamHI and HindIII restriction endonu-
cleases, and cloned into pET28-a expression vector (Novagen) by
means of T4 DNA ligase in order to form the pET28-a/rv1017
construct which carries a fusion of six histidine residues at its N-
terminus [26]. Restriction enzymes and T4 DNA ligase were
purchased from GE-Healthcare and used following the manufac-
turer’s instructions.
MtbPRPP Synthetase Heterologous Production and
Purification
E. coli BL21(DE3)pLysS cells were electroporated with the
pET28-a/rv1017 construct and grown on LB agar plates
containing kanamycin (50 mg/ml) and chloramphenicol (34 mg/
ml). Roughly 100 colonies were inoculated in 2 litres of ZYP-5052
autoinducing medium [27] containing kanamycin (50 mg/ml) and
chloramphenicol (34 mg/ml), and incubated at 37uC for 3 hrs and
at 17uC o. n. with orbital shaking at 200 rpm. Cells were collected
by centrifugation (at 60006g for 10 min at 4uC), washed with cold
PBS and stored at 220uC.
Figure 2. Assessment of the oligomeric state of MtbPRPPase. (A) SDS-PAGE of the purified MtbPRPPase. The enzyme was run in parallel with
molecular mass standards on a 12% gel and stained with Coomassie Blue R-250. Molecular mass markers were, from the top, 97, 66, 45, 31, 21.3 and
14.4 kDa, respectively. (B) Elution profile of MtbPRPPase from a Superose 6 column. The enzyme was subjected to an analytical gel-filtration on a
Superose 6HR 10/30 prepacked column. The position of the peak corresponds to a protein of 220 kDa. The inset shows the calibration curve,
prepared as reported in ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0015494.g002
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250 ml buffer A (sodium phosphate pH 8.0, 300 mM NaCl,
10 mM imidazole), supplemented with a protease inhibitor cocktail
(Sigma-Aldrich), sonicated at 800 W for 6 minutes, cleared by
ultracentrifugation, and the supernatant was applied to a HisTrap
HP column (GE-Healthcare) equilibrated in buffer A. Proteins were
eluted with scalar concentration (20 to 500 mM) of imidazole in
buffer A and fractions containing MtbPRPPase activity were
collected, concentrated and applied to a HiLoad 16/60 Super-
dex-200 column (GE-Healthcare) equilibrated in buffer B (50 mM
potassium phosphate pH 8.0, 100 mM KCl). The enzyme was
eluted by buffer B and fractions containing MtbPRPPase activity
were checked by 12% SDS-PAGE and pooled. Protein concentra-
tion was determined according to Lowry et al. [28].
Molecular Mass Determination
To determine the molecular mass of the native enzyme, the
purified MtbPRPPase (100 ml, 0.1 mg/ml) was subjected to an
analytical gel filtration on a Superose 6 HR 10/30 prepacked
column (GE-Healthcare) equilibrated in buffer B. For column
calibration the following proteins were used: thyroglobulin
(669 kDa), ferritin (440 kDa), catalase (240 kDa), aldolase
(158 kDa), albumin (68 kDa), and ribonuclease (13.7 kDa).
Enzyme Activity Assay
MtbPRPPase activity was assayed with a HPLC-based method
developed in our laroratory (unpublished data), and following the
AMP rate formation. The standard reaction mixture contained
50 mM potassium phosphate pH 8.0, 100 mM KCl, 2 mM Mg-
ATP, 2 mM R5P, in a final volume of 100 ml. After incubation at
37uC, the reaction was stopped by adding 10% (w/v) ice-cold
trichloroacetic acid, and neutralized with 200 mM K2CO3. After
centrifugation, samples (10 ml) were loaded onto a Supelcosil LC-
18 column (25064.6 mm, 5 mm particle size, Supelco Analytical).
Isocratic separation was performed in 20 mM potassium phos-
phate pH 8.0 at a flow rate of 0.8 ml/min. Analytes were
monitored at 254 nm.
The nmoles of AMP produced were determined using a
calibration curve obtained by injecting scalar amounts (0.06 to
20 nmol) of AMP, treated in the same way as that adopted for the
enzyme assay. One unit is defined as the amount of enzyme
catalyzing the production of 1 mmol of AMP per minute under
conditions here described.
Kinetic Analyses
Unless otherwise indicated, enzymatic activity was assayed at 37uC
by using various concentrations of R5P and Mg-ATP under conditions
identical to those described above except for substrates and effectors.
Figure 3. pH-activity profile of MtbPRPPase. The effect of pH on
the activity of MtbPRPPase was determined at 2 mM R5P and 5 mM Mg-
ATP, using the following buffers (100 mM): MES (#, pH range 5.5–6.5);
PIPES (,, 6–7); TES (e, 7–8), EPPS (%, 7.5–8.4); and sodium bicarbonate
(n, 8.25–9.5). All buffers contained 50 mM Pi.
doi:10.1371/journal.pone.0015494.g003
Figure 4. Activation of MtbPRPPase by ions. (A) MtbPRPPase activity response to different concentrations of phosphate (N) and sulfate (.)
anions. Concentrations of R5P and Mg-ATP were fixed at 2 mM and 5 mM, respectively. Enzyme assays were performed in 50 mM Tris-HCl pH 8.0 as
reported in the ‘‘Material and Methods’’ section. (B) MtbPRPPase activation by different concentrations of Mg
2+ (&) and Mn
2+ (m) cations. Enzyme
assays were performed at 2 mM R5P and 0.5 mM Mg-ATP fixed concentrations.
doi:10.1371/journal.pone.0015494.g004
M. tuberculosis PRPP synthetase
PLoS ONE | www.plosone.org 4 November 2010 | Volume 5 | Issue 11 | e15494The kinetic parameters were determined for R5P at 10 mM Mg-ATP
and for Mg-ATP at 2 mM R5P. In all cases the reaction was initiated
by adding R5P, and the enzyme activity was assayed at least with 12
different concentrations of substrate. All measurements were per-
formed at least in triplicate. The plot of Lineweaver-Burk was used to
determine Vmax and apparent Km values. The Hill plot obtained by
t h eE n z y m eK i n e t i cM o d u l e1 . 1( S P SS Science Software) was used to
determine the apparent S0.5 and nH values.
For the assessment of the activation by phosphate or sulfate
ions, the enzyme stored in buffer B was diluted in 50 mM Tris
HCl pH 8.0 buffer, containing 2mM Mg-ATP, lowering the
phosphate concentration to 0.25 mM. The enzyme activity was
then immediately assayed at saturating concentrations of sub-
strates, and using as assay buffer 50 mM Tris-HCl pH 8.0,
100 mM KCl, in the presence of different concentrations of
potassium phosphate or ammonium sulfate.
Thermal Stability Assays
Thermal stability was measured by incubating the enzyme
(100 mg/ml) at given temperatures in buffer B, in the absence and
in the presence of ligands. Samples were removed at intervals and
immediately assayed as described above.
Relative activity was expressed as percentage of the enzyme
activity before the incubation. t1/2 is the time required by the
enzyme to lose 50% of its initial activity at a given temperature.
The thermal denaturation was also measured by circular
dichroism spectropolarimetry. Thermal unfolding was followed
by continuous measurements of ellipticity at 220 nm at the
temperature range 50–90uC under a constant heating rate of 1uC/
min, and with a Jasco J-710 spectropolarimeter (Jasco Europe,
Cremella, Italy) equipped with a Neslab RT-11 programmable
water bath (Thermo Fisher Scientific, Waltham, MA, USA) and a
1 mm path-length cuvette. Protein concentration was 0.1 mg/ml
in buffer B. The midpoint temperatures (Tm) were calculated from
curves fitting.
Homology Modelling of MtbPRPPase
The three dimensional structure of MtbPRPPase was modelled
using, as the template, the atomic coordinates of the X-ray crystal
structure of the human ortholog in complex with AMP, cadmium
and sulfate ion (PDB code 2HCR) [23]. The program SWISS-
PDBviewer in conjunction with the SWISS-MODEL server
(http://www.expasy.org/spdbv/) was employed for building and
optimizing the model. The stereochemistry of the predicted
structure has been assessed with the program PROCHECK [29].
92.0% of residues felt in the most favoured region of the
Ramachandran plot, 8.0% in the additional allowed region with
Figure 5. Steady state kinetics of MtbPRPPase. (A) Steady state kinetics of MtbPRPPase as a function of R5P. All assays were performed at fixed
10 mM Mg-ATP, in the absence of free divalent ions (N), in the presence of 5 mM MgCl2 (&), and in the presence of 5 mM MnCl2 (m). (B) Steady state
kinetics of MtbPRPPase as a function of Mg-ATP. All experiments were performed at fixed 2 mM R5P, in the absence (N) and in the presence (#)o f
5 mM MgCl2, and as a function of Mn-ATP in the absence (m) and in the presence (n) of 5 mM MnCl2. Enzyme assay conditions are reported in the
‘‘Material and Methods’’ section.
doi:10.1371/journal.pone.0015494.g005
Table 1. Main kinetics parameters of MtbPRPPase towards
R5P in the absence and in the presence of free divalent
cations.
kcat (s
21)K m (mM) kcat/Km (s
21 mM
21)
No addition 37.061.8 0.07160.006 521.1
+Mg
2+ 35.162.3 0.07060.015 501.4
+Mn
2+ 44.762.6 0.06060.008 745.0
When present, free cations were at 5 mM fixed concentration.
doi:10.1371/journal.pone.0015494.t001
Table 2. Main kinetics parameters of MtbPRPPase towards
Mg-ATP and Mn-ATP in the absence and in the presence of
free divalent cations.
kcat (s
21)S 0.5 (mM) nH kcat/S0.5 (s
21 mM
21)
Mg-ATP 35.562.3 1.7160.09 2.660.3 20.8
Mn-ATP 46.362.4 1.7860.11 1.960.2 26.0
Mg-ATP+Mg
2+ 34.663.0 0.2660.05 1.060.2 133.1
Mn-ATP+Mn
2+ 45.162.4 0.1160.01 1.060.1 410.0
Mg-ATP+Mn
2+ 44.362.4 0.1160.01 1.060.1 402.7
When present, free cations were at 5 mM fixed concentration.
doi:10.1371/journal.pone.0015494.t002
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the modelled MtbPRPPase structure can be superimposed with a
r.m.s.d. of 0.5 A ˚ based on 303 Ca pairs (the two enzymes share a
sequence identity of 44%). The model of the MtbPRPPase-AMP
complex was obtained by superposing the predicted M. tuberculosis
structure onto the crystal structure of human template and pasting
the AMP molecule into the M. tuberculosis modelled structure.
Figures were generated with the program Pymol [30].
Results
Heterologous Expression and Purification of
M. tuberculosis PRPPase
The recombinant MtbPRPPase was expressed in E. coli
BL21(DE3)pLysS cells, and purified to homogeneity as described
in the ‘‘Material and Methods’’ section. The typical yield was
about 20 mg of purified MtbPRPPase from 1 litre of culture. The
specific activity, under standard conditions, was 59.7 U/mg. No
detectable activity was found with Mg-GTP used as substrate. As
phosphate (Pi) has been reported to be indispensable in preserving
protein stability of PRPPases, the MtbPRPPase was maintained in
50 mM phosphate, pH 8.0 [16–17,23]. In actual fact, dialysis
against buffers such as 50 mM Tris-HCl, pH 8.0 or 50 mM
Hepes-NaOH, pH 8.0 resulted in a protein precipitation and
complete loss of activity. The addition of 50 mM ammonium
sulfate or 5 mM Mg-ATP to Tris-HCl, pH 8.0 allowed the
enzyme to preserve 20% of initial activity after a period of
16 hours, whereas full activity was maintained with the addition of
50 mM Pi.
Main Characteristics of MtbPRPPase
Oligomeric state—The enzyme migrated in 12% SDS-PAGE as a
protein of apparent molecular mass of approximately 35 kDa
(Fig. 2A) and eluted from a Superose 6 column as a single
simmetric peak, corresponding to a 220 kDa protein (Fig. 2B).
These results indicated that the recombinant MtbPRPPase was a
hexamer of identical subunits.
Dependence on pH—The pH-activity profile for MtbPRPP is shown
in Figure 3. The enzyme exhibited preference for high pH values,
showing an optimum at a pH value close to 8, and possessing nearly
70%ofitsmaximalactivityatpH 9.5.TheactivityatpH 7wasonly
57% of the maximal one. The pH profile exhibited by MtbPRPPase
approached that of B. subtilis enzyme [31]
Requirements for inorganic phosphate—PRPPases are known to
require phosphate for their activity [16–17,23]. MtbPRPPase
resulted to be actually dependent on Pi for its activity: the optimal
Pi concentration ranged from 10 mM to 40 mM; higher
concentrations of Pi were inhibitory (50% inhibition at 100 mM
Pi) (Fig. 4A). SO4
22 ions were also able to stimulate the enzyme
activity, but with respect to Pi, were less effective and required
Figure 6. Inhibition of MtbPRPPase by divalent cations. (A)
Response of PRPPase activity to CuCl2 (m), CaCl2 (.) and FeCl2 (&)
different concentrations. All measurements were performed at 2 mM
R5P and 5 mM Mg-ATP, in the absence (black symbols), and in the
presence of 5 mM MgCl2 (white symbols) or 5 mM MnCl2 (gray
symbols). (B) Steady state kinetics vs Mg-ATP, at 2 mM R5P in the
absence (N) and in the presence of 0.02 mM CuCl2 (m), 0.8 mM CaCl2
(.)a n d0 . 4 m MF e C l 2 (&), concentrations. Measurements were
performed either in the absence (filled symbols) or in the presence
(open symbols) of 5 mM MgCl2 (C) Steady state kinetics vs Mn-ATP, at
2 mM R5P in the absence (N) and in the presence of 0.02 mM CuCl2
(m), 0.8 mM CaCl2 (.)a n d0 . 4 m MF e C l 2 (&), concentrations.
Measurements were performed either in the absence (filled symbols)
or in the presence (open symbols) of 5 mM MnCl2.
doi:10.1371/journal.pone.0015494.g006
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activation (Fig. 4A). On the contrary, SO4
22, at concentrations up
to 100 mM, were only faintly inhibitory.
Activation by divalent cations—It has been reported that PRPPases
are activated by free divalent cations. At subsaturating Mg-ATP
concentrations, MtbPRPPase reached half-maximum activation at
approximately 1 mM free ions (Mg
2+ and Mn
2+, 1.2 mM and
1.1 mM, respectively), although the maximal activity reached in
the presence of 5 mM Mg
2+ resulted to be roughly 80% of that in
the presence of 5 mM Mn
2+ (Fig. 4B)
Steady State Kinetics as a Function of Substrates
Concentration
Steady state kinetics of the recombinant MtbPRPPase as a
function of R5P and Mg-ATP, are shown in Figure 5. Main kinetic
parameters are summarized in Tables 1 and 2.
At saturating concentration of Mg-ATP, the enzyme exhibited
hyperbolic response to R5P (Fig. 5A), with an apparent Km of
0.071 mM. On the contrary, at saturating R5P concentration, it
showed sigmoidal behaviour towards Mg-ATP (Fig. 5B), with an
apparent S0.5 of 1.71 mM and a Hill coefficient (nH) of 2.6.
The presence of 5 mM free Mg
2+ in kinetics towards R5P did
not alter the curve profile, whereas 5 mM Mn
2+ raised the
maximal activity to 120% (Fig. 5A). As for the response of the
enzyme towards Mg-ATP, the presence of 5 mM free Mg
2+
converted the sigmoid curve into a hyperbole, lowering the
apparent S0.5 value and leaving the Vmax value unchanged (Fig. 5B
and Table 2). A similar effect was obtained by the presence of
5m MM n
2+ to the kinetics versus Mn-ATP (Fig. 5B and Table 2).
Notably, the presence of 5 mM Mn
2+ in the kinetics versus Mg-
ATP (curve profile not shown) led to kinetic parameters which
were nearly identical to those obtained for the kinetics towards
Mn-ATP (Table 2).
Inhibition by Divalent Cations
Divalent cations, such as Ca
2+ or Cd
2+, are reported to inhibit
PRPPases [31]. Figure 6A reports the inhibition curves of CuCl2,
CaCl2 and FeCl2 at 5mM Mg-ATP. All ions resulted to be
inhibitory, Cu
2+ being the most effective, with an IC50 (inhibitor
concentration lowering enzyme activity to 50%) value of 0.02 versus
0.4 and 0.8 mM of Fe
2+ and Ca
2+, respectively. The presence of
Cu
2+,C a
2+or Fe
2+ at a concentration equal to their IC50 left the
affinity for Mg-ATP unchanged or even slightly increased, as
shown by the kinetics towards this substrate (Fig. 6B, Tables 3 and
4). In addition, these ions reduced, but did not completely abolish,
the cooperativity towards Mg-ATP (nH value reduced up to 1.4 in
the case of Cu
2+, Table 3). The inhibition was not even removed
by using fully activating concentrations of free MgCl2, although in
the presence of Mg
2+ the curves vs Mg-ATP became hyperbolic.
Vmax values remained similar to those obtained in the presence of
inhibitory ions alone (Fig. 6B, Table 3). Comparable inhibitory
effects were also observed when Mn-ATP was used as the variable
substrate, although the Vmax values were slightly reduced. The
addition of free Mn
2+ abolished the enzyme cooperativity towards
the nucleoside triphosphate, leaving the Vmax values almost
unchanged (Fig 6C, Table 4).
Inhibition by ADP
Class I PRPPases are reported to be allosterically inhibited by
ADP or by GDP [17]. The inhibition curves of Mg-ADP and Mg-
GDP at subsaturating concentrations of Mg-ATP and in the
presence of 50mM Pi (Fig. 7A) showed that MtbPRPPase was
weakly sensitive to GDP (IC50.5 mM), whereas it was highly
inhibited by ADP (IC50 0.4 mM). The degree of inhibition by
ADP was higher at lower concentration of Pi (IC50, 0.26 mM at
5m MP i, Fig. S1), suggesting that ADP inhibition hindered Pi in
its activatory ability. Thus, inhibition by ADP and activation by Pi
resulted to occur by competition for binding to the same site.
To prove that ADP was actually an allosteric inhibitor of
MtbPRPPase, we assayed the enzyme activity at varying Mg-ATP
concentration, in the presence of either 0.5 mM or 1 mM Mg-
ADP, with and without 5 mM MgCl2 (Fig 7B). The presence of
the nucleoside diphosphate lowered the Vmax of the enzyme,
without affecting both the apparent S0.5 and the nH values. The
Table 3. Kinetics parameters of MtbPRPPase vs Mg-ATP with different inhibitors in the absence and in the presence of 5mM MgCl2.
no addition +MgCl2
kcat (s
21)S 0.5 (mM) nH kcat/S0.5 (s
21 mM
21)k cat (s
21)S 0.5 (mM) nH kcat/S0.5 (s
21 mM
21)
No addition 35.562.3 1.7160.09 2.660.3 20.8 34.663.0 0.2660.05 1.060.2 133.1
CuCl2 0.02 mM 21.261.7 1.3260.21 1.460.2 16.1 20.661.3 0.6760.05 1.060.1 30.7
CaCl2 0.80 mM 22.861.9 1.3360.11 1.860.3 17.1 19.860.9 0.1860.02 1.260.2 110.0
FeCl2 0.40 mM 20.961.8 1.2560.21 1.560.2 16.7 18.860.8 0.1460.01 1.160.2 134.3
doi:10.1371/journal.pone.0015494.t003
Table 4. Kinetics parameters of MtbPRPPase vs Mn-ATP with different inhibitors in the absence and in the presence of 5mM MnCl2.
no addition +MnCl2
kcat (s
21)S 0.5 (mM) nH kcat/S0.5 (s
21 mM
21)k cat (s
21)S 0.5 (mM) nH kcat/S0.5 (s
21 mM
21)
No addition 46.362.4 1.7860.11 1.960.2 26.0 45.162.4 0.1160.01 1.060.1 410.0
CuCl2 0.02 mM 37.162.0 1.3860.18 1.360.2 26.8 32.661.4 0.5060.06 1.060.1 65.2
CaCl2 0.80 mM 38.661.6 1.3560.11 1.560.1 28.5 32.261.6 0.2060.03 1.160.2 161.0
FeCl2 0.40 mM 39.563.2 1.4360.23 1.460.2 27.6 35.161.5 0.1660.02 1.160.3 219.4
doi:10.1371/journal.pone.0015494.t004
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activating cation (Vmax values unchanged), although the response
towards Mg-ATP became hyperbolic with an affinity for the
substrate similar to that displayed in the presence of Mg
2+ without
Mg-ADP (Fig. 7B, Table 5). As for the kinetics towards R5P, the
presence of Mg-ADP gave effects similar to those observed when
the Mg-ATP was used as the variable substrate (Fig 7C), the Vmax
being the only kinetic parameter affected (Table 6).
As far as other potential inhibitors are concerned [31], it is
worth mentioning that no inhibitory effects were shown by the
presence of pyrimidine nucleoside mono- or diphosphates or of
histidine, up to 2 mM (data not shown).
Thermal Stability
The enzyme thermal stability was assessed either by measuring
the activity at intervals after incubation at 62uC, or by monitoring
the thermal unfolding at increasing temperature with circular
dichroism spectropolarimetry.
MtbPRPPase resulted to be a highly stable enzyme, losing 50%
of its activity in 10 minutes of incubation at 62uC, and showing a
Tm of 69.3uC (Table 7). Mg-ATP greatly increased the protein
stability, allowing the enzyme to preserve full activity for more
than one hour when incubated in the presence of this substrate. A
protective effect was also exerted by R5P, although to a lesser
extent (t1/2 22 minutes), whereas no protection was observed in
the presence of Mg
2+ ion (Fig. 8A). Similarly, the midpoint
temperatures were shifted by the presence of substrate (70.8 and
74.5uC for ATP and R5P, respectively), but not by MgCl2
(Fig. 8B).
MtbPRPPase Three Dimensional Structure Prediction
We are acutely aware of the issue of selectivity of drug action
for inhibitors targeting the MtbPRPPase, as the mycobacterial
enzyme shares a significant degree of sequence identity with
human counterpart (sequence identity of 44%). Although the
identification of possible peculiar structural features to be
exploited for the design of specific inhibitors must wait for the
determination of the X ray crystal structure of the MtbPRPPase,
we carried out a prediction of its structure based on homology
modelling. As expected, the overall structural organization of the
mycobacterial and human enzymes appeared to be strongly
conserved (Fig. 9A and 9B) as demonstrated by the observation
that the two structures can be optimally superimposed with a
r.m.s.d. of only 0.5 A ˚ based on 303 Ca pairs. However, the
analysis of the ATP binding pocket revealed interesting
differences between the two enzymes (Fig. 9C and 9D). In
particular, two major substitutions in the residues that define the
nucleoside triphosphate binding site can be identified. In the
MtbPRPPase a glutamic acid (Glu113) occupies the structurally
equivalent position of Ala105 in the human enzyme; moreover a
histidine residue (His109) replaces Asp101 in the human PRPP
synthetase. Since MtbPRPPase shows a strong cooperativity for
Figure 7. Inhibition of MtbPRPPase by nucleoside diphos-
phates. (A) Response of MtbPRPPase activity to Mg-ADP (m), and Mg-
GDP (&) different concentrations. All measurements were performed at
2 mM R5P and 1 mM Mg-ATP. (B) Steady state kinetics vs Mg-ATP, at
2 mM R5P, in the presence of 1 mM Mg-ADP (m) and 0.5 mM Mg-ADP
(.), in the absence (filled symbols) or in the presence (open symbols) of
5 mM MgCl2. (C) Steady state kinetics vs R5P, at 5 mM Mg-ATP, in the
presence of 1 mM Mg-ADP (m) and 0.5 mM Mg-ADP (.), in the absence
(filled symbols) or in the presence (open symbols) of 5 mM MgCl2. The
circles indicate the kinetics in the absence of the inhibitor. Notably, all
measurements were performed in 50 mM potassium phosphate buffer,
pH 8.0.
doi:10.1371/journal.pone.0015494.g007
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tions based on our predicted structure.
Discussion
The biosynthesis pathway of decaprenylphosphoryl-arabinose
has been proved to be an optimal target for antitubercular drugs
[10,12]. In this context, the characterization of M. tuberculosis
phosphoribosylpyrophosphate synthetase, which is the enzyme
catalysing the second step of this metabolic pathway, is reported.
Noticeably, PRPP, which is the product of the PRPPase catalysed
reaction, is also a key metabolite for the nucleotides and for the
amino acids histidine and tryptophan synthesis. The rv1017c gene,
which encodes PRPPase, is thus essential for M. tuberculosis growth
[25].
MtbPRPPase was expressed as recombinant form, purified to
homogeneity and biochemically characterized. Although the
biochemical characterization of the MtbPRPPase was performed
using the enzyme with a hexahistidine tag attached to its N-
terminus, as shown in Figure S2, the tag did not affect the main
kinetic properties (see Materials and Methods S1).
The enzyme exhibited a hexameric quaternary structure,
specificity for Mg-ATP as substrate and requirement of phosphate
for its activity. These features allowed us to label MtbPRPP as class
I enzyme. SO4
22 mimicked the activation by Pi, although to a
lower extent (56%). On the other hand, the inhibitory effect
exhibited by Pi at high concentrations was negligible in the case of
SO4
22. In this respect, MtbPRPP turned out to be quite similar to
the enzyme from B. subtilis and mammals [22,32–33].
PRPPAses require both free Mg
2+ ion as an essential activator
and Mg-ATP as a substrate. Free ion may induce and properly
stabilize the open conformation of the so-called flexible loop which
binds Mg-ATP at the active site [34–35]. In the absence of free
Mg
2+, MtbPRPPase showed homotropic cooperativity towards
Mg-ATP, which was the cause of a relatively low affinity for this
substrate (apparent S0.5, 1.71 mM). The presence of free Mg
2+
abolished the cooperativity versus Mg-ATP (nH, 1) and lowered the
apparent S0.5, suggesting that it activated the enzyme, behaving as
an allosteric effector. Moreover, the kinetic properties displayed by
MtbPRPPase in the absence and in the presence of the activator
Mg
2+ could fulfil the requirements of the K-type allosteric enzyme
of the model described by Monod [36]. Comparable heterotropic
activation was also exerted by Mn
2+, which resulted even more
effective than Mg
2+ (Table 2) whether the enzyme used Mg-ATP
or Mn-ATP as a variable substrate. In this respect, MtbPRPP
showed to be different from other class I enzymes, which display
maximal activation in the presence of free Mg
2+ ions [17,31,37].
Thermal stability assays allowed us to evidence conformational
changes caused by the presence of ligands (Fig. 8). Whereas
MtbPRPPase exhibited a more stable conformation in the presence
of Mg-ATP (t1/2, .2hrs versus 109200 of the enzyme in the absence
of ligands), the presence of free Mg
2+ ions did not lead to any
increased protein stability (t1/2,1 1 9400), suggesting that the
binding of the free activating ion did not induce large
rearrangements of the protein. Thus, keeping in consideration
previous data obtained from crystallographic studies on B. subtilis
enzyme [22,35], we hypothesize that the binding of the free Mg
2+
to its site would induce a local conformational change at the active
site of the single subunits, stabilizing the open conformation of the
flexible loop and abolishing the cooperativity of the Mg-ATP
binding sites, but leaving the overall conformation of the enzyme
unchanged. On the other hand, the binding of Mg-ATP to one
subunit would lead to overall enzyme conformational changes,
thus inducing the stabilization of the open active site conformation
in the next subunits, and increasing their affinity for Mg-ATP.
Divalent cations, such as Ca
2+ and Cd
2+, have been reported to
inhibit PRPPase activity [32,34]. MtbPRPPase was inhibited by
Ca
2+ (IC50, 0.8 mM), but the effect of this ion resulted to be less
effective than that observed in B. subtilis and human enzymes
[32,34]. In actual fact, a higher inhibition was found when the
enzyme activity was assayed in the presence of Cu
2+ ions (IC50,
0.02 mM). However, in all cases, the reduction of the activity was
accompanied by a decrease in the cooperativity towards Mg-ATP
and a slight increase in the affinity for this substrate (Table 3). The
inhibition was only partially removed by the addition of either free
Table 5. Kinetics parameters of MtbPRPPase vs Mg-ATP with different ADP concentrations in the absence and in the presence of
5mM MgCl2.
no addition +MgCl2
kcat (s
21)S 0.5 (mM) nH kcat/S0.5 (s
21 mM
21)k cat (s
21)S 0.5 (mM) nH kcat/S0.5 (s
21 mM
21)
No addition 35.562.3 1.7160.09 2.660.3 20.8 34.663.0 0.2660.05 1.060.2 133.1
Mg-ADP 0.5 mM 9.560.8 1.6960.13 2.460.2 5.6 10.660.9 0.2960.06 1.060.2 36.6
Mg-ADP 1.0 mM 5.060.7 2.1060.31 2.560.3 2.4 5.360.4 0.3160.02 1.060.1 17.1
doi:10.1371/journal.pone.0015494.t005
Table 6. Kinetics parameters of MtbPRPPase vs R5P with different ADP concentrations in the absence and in the presence of 5mM
MgCl2.
no addition +MgCl2
kcat (s
21)K m (mM) kcat/Km (s
21 mM
21)k cat (s
21)K m (mM) kcat/Km (s
21 mM
21)
No addition 37.061.8 0.07160.006 521.1 35.162.3 0.07060.015 501.4
Mg-ADP 0.5 mM 9.060.2 0.10260.02 90.0 8.960.4 0.12860.01 69.5
Mg-ADP 1.0 mM 5.160.1 0.12160.01 42.5 4.960.11 0.12160.02 40.5
doi:10.1371/journal.pone.0015494.t006
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2+ or free Mn
2+ (Vmax almost unchanged, but cooperativity
totally abolished). In addition, in the case of Cu
2+, the presence of
either Mg
2+ or Mn
2+ resulted in apparent S0.5 values higher than
those in the presence of the free activating ions alone. All in all,
these results suggest that the inhibitory ion can bind to both the
free cation site, leading to a partial enzyme activation (nH and
apparent S0.5 values reduced), and the Mg-ATP site, lowering the
Vmax. Interestingly, the effectiveness of divalent cations, either
activatory or inhibitory, seems to be related to their ionic radius.
Besides this, the behaviour towards Mg
2+,M n
2+ and Ca
2+ of
MtbPRPPase differed from that of the B. subtilis and the human
enzymes (both more activated by Mg
2+ than Mn
2+) and strongly
inhibited by Ca
2+ [31,32,37], thus suggesting a different geometry
of the free cation binding site. Figure 10 shows the sequence
alignment of the human, B. subtilis and M. tuberculosis cation
binding site, as deduced from the B. subtilis structure [35], and
obtained using Multalin 5.4.1 [38]. Arg
180 (B. subtilis numbering),
in the absence of cation, establishes a hydrogen bonding network
with two aspartic acid residues (Asp
174 and Asp
223) devoted to the
free Mg
2+ binding, and moves away to a new aspartic acid residue
(Asp
133) in the presence of the ion. In the MtbPRPPase, Arg
180,
which is also conserved in the human enzyme, is substituted by an
isoleucine, whereas two arginines are located one and three
residues behind, respectively. These structural differences could
very likely be the reason for a different free cation site topology,
thus accounting for the different ion specificity.
It is known that class I enzymes are allosterically inhibited by
purine diphosphate nucleosides [31–32]. MtbPRPPase acted as the
enzymes of this class (Fig. 7A), with non-competitive inhibition by
Mg-ADP, either in the absence or in the presence of free Mg
2+.
Similarly to the B. subtilis and Salmonella typhimurium enzymes
[31,39], MtbPRPPase was only weakly inhibited by Mg-GDP,
distinguishing itself from the mammal enzymes which were more
affected by this nucleotide (IC50, 10-fold higher) [32–33]. On the
other hand, MtbPRPPase was more sensitive to inhibition by ADP
than B. subtilis enzyme (IC50, 4-fold lower) [31], to this respect
behaving like mammal enzymes [32–33]. Interestingly, the
concentration of the ADP needed by MtbPRPPase for half-
maximal inhibition increased with increasing Pi concentration,
thus supporting the conclusions of previous studies that indicate
the presence of a regulatory site to which both inhibitory ADP and
activatory Pi could bind [22]. That MtbPRPPase was regulated by
ADP in an allosteric manner resulted by the kinetic responses to
substrates concentrations at two different concentrations of ADP.
In fact (Figure 7A and 7B, Table 5 and 6) Vmax was the only
parameter affected. Therefore, MtbPRPPase underwent the
inhibition by ADP fully meeting the uncommon requirements of
the V-type allosteric enzyme described by Monod et al. [36].
In conclusion, the biochemical investigation on PRPPase from
M. tuberculosis allows us to add a well-characterized member to
class I enzymes, and to contribute to the elucidation of the
regulatory properties of this complex enzyme involved in
nucleotides and in the mycobacterial cell wall biosynthesis. The
picture emerging from these studies is that of a ‘‘chameleon’’
enzyme which adopts different conformations in response to a
variety of allosteric effectors, either positive or negative, thus finely
adapting the synthesis of PRPP to the variable cell demands. The
enzyme characterization may represent the starting point for the
development of inhibitors for antitubercular drug design, also in
the light of the structural differences with respect to the human
counterpart, as suggested by the MtbPRPPase three dimensional
structure prediction. Our model supports the notion that the
different kinetics shown by the mycobacterial and human
PRPPase are likely due to peculiar structural traits of the
nucleoside triphosphate binding pocket and suggests that the
Figure 8. Thermal stability of MtbPRPPase. (A) Thermal stability of the MtbPRPPase at 62uC. The enzyme was incubated in 50 mM potassium
phosphate pH 8.0, 100 mM KCl, in the absence of ligands (#) and in the presence of 5 mM Mg-ATP (%), 5 mM R5P (,) and 5 mM MgCl2 (n).
Aliquots were collected at intervals for measuring residual activity. (B) Thermal unfolding kinetics of the MtbPRPPase. The enzyme denaturation was
monitored by circular dichroism spectropolarimetry, in the absence of ligands (#) and in the presence of 5 mM Mg-ATP (%), 5 mM R5P (,) and
5 mM MgCl2 (n).
doi:10.1371/journal.pone.0015494.g008
Table 7. Thermal stability parameters of MtbPRPPase in the
absence and in the presence of ligands.
t1/2 62uC (min) Tm (uC)
No addition 109250 69.360.1
MgCl2 5m M 1 1 9400 69.860.1
R5P 5 mM 229250 70.860.3
Mg-ATP 5 mM Stable 74.560.2
doi:10.1371/journal.pone.0015494.t007
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it is worth mentioning that M. tuberculosis ATP phosphoribosyl
transferase (HisG) (the enzyme catalysing a reaction one step
downstream PRPPase along the same pathway and also showing a
significant degree of sequence identity with the human ortholog),
has been successfully approached for the discovery of inhibitors
selective toward the M. tuberculosis enzyme by exploiting the PRPP
binding site in structure based virtual screening [40]. Therefore,
although we recognise that the issue of the selectivity of inhibitor
action is a major concern in the case of MtbPRPPase, both our
extensive biochemical investigation as well as a foreseen more
robust structural characterization, may prove to be useful for the
design of potent and highly specific inhibitors.
Figure 9. Homology modelling of MtbPRPPase. (A) Ribbon representation of the crystal structure of the dimer of human PRPPase in complex
with AMP, cadmium and sulfate [23] (PDB code 2HCR) that was used as the template for the homology modelling. The AMP and sulfate molecules are
represented as ball-and-sticks. (B) Ribbon representation of the predicted structure of the MtbPRPPase dimer. The AMP and sulfate molecules are
drawn as ball-and-sticks. (C) The adenosine triphosphate binding site in human PRPPase. The AMP molecule and key residues that define the
nucleotide binding pocket are labelled and represented as ball-and-sticks. (D). The adenosine triphosphate binding site as emerging in the predicted
structure of MtbPRPPase where the AMP and protein residues building the binding pocket are labelled and depicted as ball-and-sticks. In both (C)
and (D), the asterisks indicate the two residues that are structurally not conserved in the two enzymes.
doi:10.1371/journal.pone.0015494.g009
Figure 10. Alignment of free ion binding site sequences.
Alignment of free ion binding site sequences of B. subtilis, human PRS1
and M. tuberculosis PRPPases was performed with Multalin 5.4.1. Black
arrows point to the aspartic residues involved in the binding of the free
ion, grey arrow to the Arg
180 (B. subtilis numbering). The boxes
highlight the positions of the two arginines in the MtbPRPPase
sequence.
doi:10.1371/journal.pone.0015494.g010
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Figure S1 Inhibition of MtbPRPPase by ADP at different
Pi concentrations. Response of MtbPRPPase activity to Mg-
ADP different concentrations, in the presence of 5 mM (n) and
50 mM potassium phosphate (m). All measurements were
performed in 50 mM Tris-HCl pH 8.0, at 2 mM R5P and
1 mM Mg-ATP. (TIF)
Figure S2 Characterization of the recombinant
MtbPRPPase after the removal of the His-tag.
MtbPRPPase, after the removal of the hexahistine tag, was
kinetically characterized and compared with the kinetic properties
of the enzyme provided with His-tag. Closed symbols indicate the
enzyme with His-tag attached to its N-terminus, open symbols the
enzyme without His-tag. (A) Steady state kinetics of enzyme as a
function of R5P at fixed 10 mM concentration of Mg-ATP, in the
absence of free divalent cations (N), and in the presence of 5 mM
MgCl2 (&); (B) Steady state kinetics of MtbPRPPase as a function
of Mg-ATP at fixed 2 mM concentration of R5P, in the absence
(N) and in the presence (&) of 5 mM MgCl2. (C) Response of
activity to CuCl2 (m), CaCl2 (.) and FeCl2 (&) different
concentrations, at 2 mM R5P and 5 mM Mg-ATP. (D) Response
of activity to Mg-ADP different concentrations (m), at 2 mM R5P
and 1 mM Mg-ATP. (TIF)
Materials and Methods S1 Expression and Purification
of Recombinant MtbPRPPase Devoid of His-tag. (DOC)
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